{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:48:05Z","timestamp":1792273685075,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Suzhou Major Disease Multicenter Clinical Research Project","award":["DZXYJ202508"],"award-info":[{"award-number":["DZXYJ202508"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12072-026-11132-1","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:15:54Z","timestamp":1785165354000},"page":"1372-1381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"20","author":[{"given":"Shi-ping","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-kai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8576-2243","authenticated-orcid":false,"given":"Han","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"2","key":"11132_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United Eur Gastroenterol J. 2024;12(2):177\u2013186. https:\/\/doi.org\/10.1002\/ueg2.12525","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"11132_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/ijms26041778","volume":"26","author":"AG Devasia","year":"2025","unstructured":"Devasia AG, Ramasamy A, Leo CH. Current therapeutic landscape for metabolic dysfunction-associated steatohepatitis. Int J Mol Sci. 2025;26(4):1778. https:\/\/doi.org\/10.3390\/ijms26041778","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11132_CR3","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","volume":"77","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Yu J. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options. Pharmacol Rev. 2025;77(2):100018. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018","journal-title":"Pharmacol Rev"},{"issue":"1","key":"11132_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x","journal-title":"Lipids Health Dis"},{"issue":"48","key":"11132_CR5","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh A, Sohal A, Batta A. GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol. 2024;30(48):5205\u20135211. https:\/\/doi.org\/10.3748\/wjg.v30.i48.5205","journal-title":"World J Gastroenterol"},{"key":"11132_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejim.2024.01.005","volume":"122","author":"A Armandi","year":"2024","unstructured":"Armandi A, Bugianesi E. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Eur J Intern Med. 2024;122:20\u201327. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.005","journal-title":"Eur J Intern Med"},{"issue":"716","key":"11132_CR7","doi-asserted-by":"publisher","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Friedman SL. Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med. 2023;15(716):eadi0759. https:\/\/doi.org\/10.1126\/scitranslmed.adi0759","journal-title":"Sci Transl Med"},{"issue":"3","key":"11132_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24(3):171\u2013189. https:\/\/doi.org\/10.1038\/s41573-024-01084-2","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"11132_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","volume":"36","author":"MA Tincopa","year":"2024","unstructured":"Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metab. 2024;36(5):912\u2013926. https:\/\/doi.org\/10.1016\/j.cmet.2024.03.011","journal-title":"Cell Metab"},{"issue":"1","key":"11132_CR10","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/ANNALS-24-02933","volume":"178","author":"SMJ Ali","year":"2025","unstructured":"Ali SMJ, Lai M. Metabolic dysfunction-associated steatotic liver disease. Ann Intern Med. 2025;178(1):ITC1\u2013ITC16. https:\/\/doi.org\/10.7326\/ANNALS-24-02933","journal-title":"Ann Intern Med"},{"issue":"2","key":"11132_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","volume":"81","author":"CN Yashaswini","year":"2024","unstructured":"Yashaswini CN, Qin T, Bhattacharya D, et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J Hepatol. 2024;81(2):207\u2013217. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.014","journal-title":"J Hepatol"},{"issue":"6","key":"11132_CR12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/dom.15524","volume":"26","author":"MF Abdelmalek","year":"2024","unstructured":"Abdelmalek MF, Harrison SA, Sanyal AJ. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metab. 2024;26(6):2001\u20132016. https:\/\/doi.org\/10.1111\/dom.15524","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"11132_CR13","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.3390\/ijms26072959","volume":"26","author":"JE Mej\u00eda-Guzm\u00e1n","year":"2025","unstructured":"Mej\u00eda-Guzm\u00e1n JE, Belmont-Hern\u00e1ndez RA, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N. Metabolic-dysfunction-associated steatotic liver disease: molecular mechanisms, clinical implications, and emerging therapeutic strategies. Int J Mol Sci. 2025;26(7):2959. https:\/\/doi.org\/10.3390\/ijms26072959","journal-title":"Int J Mol Sci"},{"issue":"7","key":"11132_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u2013474. https:\/\/doi.org\/10.1038\/s41569-023-00849-3","journal-title":"Nat Rev Cardiol"},{"key":"11132_CR15","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"issue":"5","key":"11132_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","volume":"73","author":"A Wester","year":"2024","unstructured":"Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagstr\u00f6m H. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut. 2024;73(5):835\u2013843. https:\/\/doi.org\/10.1136\/gutjnl-2023-330962","journal-title":"Gut"},{"key":"11132_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105\u2013906","journal-title":"Int J Surg"},{"key":"11132_CR18","unstructured":"Online tool to evaluate the certainty and importance of the evidence-GRADE pro. Available from: https:\/\/www.gradepro.org\/"},{"issue":"9","key":"11132_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1590\/s0004-27302013000900005","volume":"57","author":"H Fan","year":"2013","unstructured":"Fan H, Pan Q, Xu Y, Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol. 2013;57(9):702\u2013708. https:\/\/doi.org\/10.1590\/s0004-27302013000900005","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"6","key":"11132_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/dmrr.2561","volume":"30","author":"N Shao","year":"2014","unstructured":"Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(6):521\u2013529. https:\/\/doi.org\/10.1002\/dmrr.2561","journal-title":"Diabetes Metab Res Rev"},{"issue":"10019","key":"11132_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"2","key":"11132_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64(2):399\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.038","journal-title":"J Hepatol"},{"issue":"8","key":"11132_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1753-0407.12555","volume":"9","author":"W Feng","year":"2017","unstructured":"Feng W, Gao C, Bi Y, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800\u2013809. https:\/\/doi.org\/10.1111\/1753-0407.12555","journal-title":"J Diabetes"},{"issue":"12","key":"11132_CR24","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/dom.13007","volume":"19","author":"J Khoo","year":"2017","unstructured":"Khoo J, Hsiang J, Taneja R, Law NM, Ang TL. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial. Diabetes Obes Metab. 2017;19(12):1814\u20131817. https:\/\/doi.org\/10.1111\/dom.13007","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"11132_CR25","doi-asserted-by":"publisher","first-page":"BSR20181304","DOI":"10.1042\/BSR20181304","volume":"38","author":"F Tian","year":"2018","unstructured":"Tian F, Zheng Z, Zhang D, He S, Shen J. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep. 2018;38(6):BSR20181304. https:\/\/doi.org\/10.1042\/BSR20181304","journal-title":"Biosci Rep"},{"issue":"5","key":"11132_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","volume":"39","author":"J Khoo","year":"2019","unstructured":"Khoo J, Hsiang JC, Taneja R, et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 2019;39(5):941\u2013949. https:\/\/doi.org\/10.1111\/liv.14065","journal-title":"Liver Int"},{"issue":"6","key":"11132_CR27","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology. 2019;69(6):2414\u20132426. https:\/\/doi.org\/10.1002\/hep.30320","journal-title":"Hepatology"},{"key":"11132_CR28","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","volume":"170","author":"W Guo","year":"2020","unstructured":"Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020;170:108487. https:\/\/doi.org\/10.1016\/j.diabres.2020.108487","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"11132_CR29","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020;63(11):2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7","journal-title":"Diabetologia"},{"issue":"5","key":"11132_CR30","doi-asserted-by":"publisher","first-page":"e3292","DOI":"10.1002\/dmrr.3292","volume":"36","author":"L Liu","year":"2020","unstructured":"Liu L, Yan H, Xia M, et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev. 2020;36(5):e3292. https:\/\/doi.org\/10.1002\/dmrr.3292","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"11132_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","volume":"44","author":"LY Zhang","year":"2020","unstructured":"Zhang LY, Qu XN, Sun ZY, Zhang Y. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2020;44(5):674\u2013680. https:\/\/doi.org\/10.1016\/j.clinre.2020.01.007","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"11132_CR32","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54(9):1150\u20131161. https:\/\/doi.org\/10.1111\/apt.16608","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"11132_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"6","key":"11132_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"11132_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/apt.17598","volume":"58","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Armstrong MJ, Funuyet-Salas J, et al. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial. Aliment Pharmacol Ther. 2023;58(4):395\u2013403. https:\/\/doi.org\/10.1111\/apt.17598","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"11132_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"4","key":"11132_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755","journal-title":"N Engl J Med"},{"issue":"7","key":"11132_CR38","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"issue":"9","key":"11132_CR39","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","volume":"22","author":"SS Shankar","year":"2024","unstructured":"Shankar SS, Daniels SJ, Robertson D, et al. Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis. Clin Gastroenterol Hepatol. 2024;22(9):1847-1857.e11. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11132_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.006","journal-title":"J Hepatol"},{"issue":"5","key":"11132_CR41","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.jhepr.2025.101363","volume":"7","author":"A Moolla","year":"2025","unstructured":"Moolla A, Poolman T, Othonos N, et al. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD. JHEP Rep. 2025;7(5):101363. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101363","journal-title":"JHEP Rep"},{"issue":"21","key":"11132_CR42","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"6","key":"11132_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","volume":"82","author":"L Xiang","year":"2025","unstructured":"Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(6):967\u2013978. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006","journal-title":"J Hepatol"},{"issue":"11","key":"11132_CR44","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.jhepr.2025.101483","volume":"7","author":"SK Browne","year":"2025","unstructured":"Browne SK, Suschak JJ, Tomah S, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: a randomized, controlled clinical trial. JHEP Rep. 2025;7(11):101483. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101483","journal-title":"JHEP Rep"},{"issue":"10520","key":"11132_CR45","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406(10520):2644\u20132655. https:\/\/doi.org\/10.1016\/S0140-6736(25)02114-2","journal-title":"Lancet"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11132-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11132-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11132-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:18:57Z","timestamp":1792271937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11132-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11132"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11132-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}